RABIES VACCINE MARKET ANALYSIS (2020-2027) - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

RABIES VACCINE MARKET ANALYSIS (2020-2027)

Description:

Read here the market research report on the “Rabies Vaccine Market" published by CMI Team – PowerPoint PPT presentation

Number of Views:7
Date added: 2 November 2020
Slides: 21
Provided by: kunalbhuta
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: RABIES VACCINE MARKET ANALYSIS (2020-2027)


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
RABIES VACCINE MARKET ANALYSIS (2020-2027)
  • Rabies Vaccine Market Industry Insights,
    Trends, Outlook, and Opportunity Analysis 2020-
    2027

3
  • Rabies is a viral zoonotic disease caused through
    a dogs bite which leads to progressive and fatal
    inflammation of the brain and spinal cord. There
    are two type of rabies furious rabies and
    paralytic rabies. Symptoms accompanied with
    furious rabies are hyperactivity and
    hallucination. Paralytic rabies can cause coma
    and paralysis. Rabies seems fatal disease but it
    can be controlled through vaccines and medicines
    which have long been available to prevent death
    by rabies. According World Health Organization
    (WHO), globally rabies cause fatalities nearly
    10,000 people yearly and almost 99 cases are due
    to dog bites. Symptoms caused by rabies are
    wound, fever with pain near the wound, tingling,
    pricking at wound site, and if not treated
    properly it can lead to cardiac or respiratory
    arrest. According to World Health Organization
    (WHO), in 2017, rabies caused 59,000 deaths
    annually in 150 countries with 95 cases in rural
    districts.

4
Global Rabies Vaccines Market- Drivers
  • Key players are focused on research and
    development strategies which are expected to
    drive the global rabies vaccine market growth
    during the forecast period. For instance, in
    2017, CPL Laboratories (India), a joint venture
    biotechnology company established in 2009 by
    Novavax Inc., USA and Cadila Pharmaceuticals
    Limited, stated that Nano- particle vaccine of
    baculvirous-derived glycoprotein, a four dose
    regime vaccine is in phase-3 human trial, and is
    expected to be approved by 2021.

5
  • In U.S., rabies in early 1960 to 2000 was
    negligible, and witnessed a sudden rise resulting
    in 100 cases annually.  Although the fatalities
    were rare, lack of awareness towards rabies is
    proving to be a risk. From 1960 to 2018, 127
    cases of rabies were reported in U.S. from dog
    bites and bat bites. Whereas in Asia, rabies is a
    major burden, accounting for almost 35,000
    deaths, fatalities caused by rabies in India are
    55.  In Africa, an estimated 21,476 human deaths
    occur due to dog bite rabies, Africa spends less
    on the post exposure prophylaxis treatment of
    rabies and have highest mortality rate due to
    rabies. Central Asia and Middle East Asia have an
    estimated 1875 and 229 fatalities yearly. These
    factors are is expected to drive the global
    rabies vaccines market growth during the forecast
    period.

6
Global Rabies Vaccines Market-Impact of COVID-19
Analysis on the Global Rabies Vaccine Market
  • The impact of COVID-19 on the global rabies
    vaccine market has affected every market around
    the globe in a negative way. As the world still
    struggles to recover from the COVID-19 situation
    it will take a long time for every market to
    recover its losses. People have been reluctant to
    visit the physicians for vaccination due to
    social distancing. As per the situation, the
    impact of COVID-19 has strongly affected the
    future market opportunities, revenue growth
    graph, and the profit gains of the business for
    global rabies vaccine market.  

7
Global Rabies Vaccines Market - Restraints
  • Emerging economies in Africa and Asia are
    expected to witness a major burden of rabies due
    to lack of awareness and costly treatment. Post
    exposure, prophylaxis is a dose regime for dog
    mediated rabies. According to World Health
    Organization (WHO), in 2017, the estimated cost
    of PEP was US 1.5 million, which can make it
    unaffordable in mid- or low-income countries and
    restrain the growth of the global rabies vaccines
    market during the forecast period.   

8
Global Rabies Vaccine Market Regional Analysis
  • Regional segmentation of the global rabies
    vaccine market includes North America, Latin
    America, Europe, Asia Pacific, Middle East, and
    Africa. North America is projected to dominate
    the global rabies vaccines market with the
    largest share during the forecast period. The
    rising investments by governments in the public
    sector, as well as programs to eradicate rabies
    are favouring growth of the market in the region.
    For instance, countries in North America in 2008
    established the North America Rabies Management
    Plan, by assessing and defining the needs,
    priorities to control rabies and eventually
    eliminate it from Canada, Mexico, and the U.S.

9
  • According to the European Centre for Disease
    Prevention and Control, in 2014 only 3 cases of
    rabies were reported in Europe, whereas Europe
    being the highest vaccine manufacturer for
    rabies. Key market players in Europe are
    GlaxoSmithKline, SanofiPasteur and Novartis AG.
  • Furthermore, the market in Asia Pacific is
    expected to witness significant growth owing to
    active involvement by manufacturers in Asia
    Pacific countries such as China, Japan and India
    regarding development of innovative rabies
    vaccine and its substitutes. In February 2018,
    BioNote, Inc., a South Korean veterinary
    diagnostic company operating in rabies
    diagnostics, announced the launch of a new
    immune-fluorescent device, Vcheck, which can
    measure diagnostic result values with the help of
    fluorescent materials which help in detecting the
    zoonotic disease in animals.

10
  • The market in Asia Pacific is expected to witness
    new entrants and is a major competitive market
    due to the burden of rabies. According to data
    published by the World Health Organization (WHO)
    in 2017, India accounts for 59.9 of deaths due
    to rabies in Asia, and 35 of deaths globally.
    Major players operating in the region are Yisheng
    Biopharma, Serum Institute of India, Zuventus,
    and Bharat Biotech Ltd. Moreover companies such
    as Yisheng Laboratories and CPL Laboratories
    (India) have vaccine candidates in clinical
    trials.

11
Global Rabies Vaccine Market- Competitive
Landscape
  • Key players operating in global rabies vaccine
    market are Sanofi S.A., Novartis International
    AG, Serum Institute of India Pvt. Ltd, Indian
    Immunologicals Limited, Bharat Biotech Ltd,
    Zuventus HealthCare Ltd., Cpl Biologicals Private
    Limited, Yisheng Biopharma Co., Ltd,
    GlaxoSmithKline plc, Bavarian Nordic A/S, and
    Chiron Behring Vaccines Private Limited.

12
Key Developments-
  • In 2016, Serum Institute of India, developed new
    rabies vaccine, RABIVAS-S, for countries with
    highest burden of rabies.
  • The World Organization for Animal Health (OIE), a
    vaccine bank, was established in 2012 with
    production order for rabies vaccine of 50,000
    doses in 31st December 2016. The OIE recorded 16
    million doses of vaccines in 24 countries for
    pre- and post-exposure prophylaxis treatment for
    rabies.
  • In 2019, Yisheng Biopharma (Singapore) Pte Ltd
    stated that development of adjuvant rabies
    vaccine, PIKA which is composed of RABIPUR and
    polyisonic-polycytidcyclic acid, has completed
    its phase 2 clinical trial.

13
  • In 2019, GlaxoSmithKline divested its rabies and
    tick-borne vaccine to Bavarian Nordic, and
    incurred payment of 36 million from Bavarian
    Nordic.
  • In 2019, Asian subsidiary of GlaxoSmithKline
    divested its Chiron Behring Vaccines unit in
    Gujarat, India to domestic clinical biotechnology
    company, Bharat Biotech.
  • In 2019, Wuhan Institute of Virology announced
    positive results of a novel rabies vaccine in
    pre-clinical test. The novel vaccine is a live
    attenuated vaccine VEEV-RABV-G.
  • In June 18, 2020 Bavarian Nordic A/S and Valneva
    SE announced a partnership for marketing and
    distribution of rabies and tick-borne vaccines in
    selected European countries and Canada.

14
Global Rabies Vaccine Market - Taxonomy
  • By Vaccine Type-
  • In 2016, Serum Institute of India, developed new
    rabies vaccine, RABIVAS-S, for countries with
    highest burden of rabies.
  • Neutral vaccine
  • Suckling mouse brain vaccine
  • Semble rabies vaccine
  • Nonneutral vaccine
  • Duck embryo vaccine
  • Cell culture vaccine

15
  • By Vaccine Type-
  • Human diploid cell vaccine (HDCV)
  • Purified chick embryo cell vaccine (PCECV)
  • Purified Vero cell rabies vaccine (PVRV)
  • Primary hamster kidney cell vaccine (PHKCV)
  • By Route of Administration-
  • Intra-muscular vaccine
  • Oral vaccine (Veterinary use)

16
  • By End User-
  • Hospitals
  • Clinics
  • Vaccination Centres
  • By Region-
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

17
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Referencehttps//www.coherentmarketinsights.com/o
    ngoing-insight/rabies-vaccine-market-4005

18
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

19
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

20
  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com